Art

J-GLOBAL ID：201502234015821477   Reference number：15A0666775

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

未治療の進展型小細胞肺癌における化学療法併用ベバシズマブのランダム化第II~III相試験 IFCT-0802試験からの結果

Author (22)： PUJOL J.-L. (Univ. Hospital, Montpellier) ,  LAVOLE A. (AP-HP Hospital Tenon, Paris) ,  QUOIX E. (Univ. Hospital, Strasbourg) ,  MOLINIER O. (Le Mans Hospital, Le Mans) ,  SOUQUET P.-J. (Pierre-Benite Hospital, Lyon) ,  BARLESI F. (Aix-Marseille Univ.) ,  LE CAER H. (Draguignan Hospital, Draguignan) ,  MORO-SIBILOT D. (Univ. Hospital, Grenoble) ,  FOURNEL P. (Loire Cancer Inst., St-Priest-en-Jarez) ,  OSTER J.P. (Colmar Hospital, Colmar) ,  CHATELLAIN P. (Alpes-Leman Hospital, Ambilly) ,  BARRE P. (Jean Rougier Hospital, Cahors) ,  JEANNIN G. (Gabriel Montpied Univ. Hospital, Clermont-Ferrand) ,  MOURLANETTE P. (Private Hospital, Cornebarrieu) ,  DEROLLEZ M. (Private Hospital, Maubeuge) ,  HERMAN D. (Nevers Hospital, Nevers) ,  RENAULT A. (Pau Hospital, Pau) ,  DAYEN C. (Saint-Quentin Hospital, Saint-Quentin) ,  LAMY P.J. (Regional Cancer Inst., Montpellier) ,  LANGLAIS A. (French Cooperative Thoracic Intergroup(IFCT), Paris) ,  MORIN F. (French Cooperative Thoracic Intergroup(IFCT), Paris) ,  ZALCMAN G.
Material： Annals of Oncology  (Ann Oncol)
Volume： 26  Issue： 5  Page： 908-914  Publication year： May. 2015 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： RCT ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0666775&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of respiratory system  (GI04000G)

Substance index (3)： Etoposide ,  Epirubicin ,  Cyclophosphamid

Reference (11)：

• Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Oncol 2013; 8: 587-598.
• Pujol JL, Breton JL, Gervais R et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007; 25: 3945-3951.
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
• Spigel DR, Townley PM, Waterhouse DM et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011; 29: 2215-2222.
• Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973; 4: 31-42.

Terms in the title (7)： 治療 ,  進展型小細胞肺癌 ,  化学療法 ,  併用 ,  ベバシズマブ ,  ランダム化 ,  試験